Targeted engineered exosomes alleviate myocardial infarction injury by enhancing angiogenesis and improving mitochondrial function
Journal of Controlled Release · 2026-01 · 389 · 114404
DOI: 10.1016/j.jconrel.2025.114404 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-01. Verfasst von Haixia Luo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an 710038, China. Hauptthemen laut MEDLINE: Exosomes, Myocardial Infarction, Neovascularization, Physiologic, Mitochondria. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Fourth Military Medical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Myocardial infarction (MI) remains a leading cause of global mortality, where acute ischemic injury and chronic cardiomyocyte dysfunction are pathological mechanisms leading to heart failure (HF). Current therapies fail to effectively halt this progression. Although VegfA delivery shows potential for revascularization, its clinical translation is limited by inefficient delivery systems. Exosomes, as emerging nanocarriers, hold promise but suffer from poor targeting. Here, a dual mRNA-loaded exosome platment (ExoIC-LNV) for synergistic therapy is developed. The exosome is functionally designed with ischemic myocardium targeting peptide (IMTP) and Connexin 43 (Cx43) to accumulate at the ischemic region. Meanwhile, ExoIC-LNV contains VegfA mRNA and Ndufs1 mRNA, based on the binding properties of L7Ae. The results demonstrate that ExoIC-LNV achieve significantly higher enrichment in ischemic tissue compared to single targeted modified exosomes. The Ndufs1-loaded exosomes improve mitochondrial function in hypoxic cardiomyocytes, and the VefgA-loaded exosomes promote angiogenesis in ischemic tissue. ExoIC-LNV loaded with dual mRNAs exhibit superior mitochondrial improvement while promoting angiogenesis, resulting in better cardiac function improvement through dual-pathway modulation after MI. Through multiple tail vein injections, the benefical proteins accumulate in the ischemic area, providing better prospects for clinical translation. This study proposes a targeted exosome-based strategy for combating pathological remodeling in MI and represents a possible approach for HF prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an 710038, China.
- Department of Cardiology, Xianyang Central Hospital, Xianyang 721000, China.
- Department of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an 710038, China. Electronic address: qibingchao2020@163.com.
- Department of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an 710038, China. Electronic address: profleeyan@163.com.
Förderung
- Fourth Military Medical University
- National Natural Science Foundation of China
Zitieren
APA
Luo, H., Wang, K., Zhang, Y., Li, T., Jia, X., Feng, R., Zhao, R., Yu, R., Hu, L., Zhang, M., Qi, B., & Li, Y. (2026). Targeted engineered exosomes alleviate myocardial infarction injury by enhancing angiogenesis and improving mitochondrial function. Journal of Controlled Release, 389, 114404. https://doi.org/10.1016/j.jconrel.2025.114404
Vancouver
Luo H, Wang K, Zhang Y, Li T, Jia X, Feng R, et al. Targeted engineered exosomes alleviate myocardial infarction injury by enhancing angiogenesis and improving mitochondrial function. Journal of Controlled Release. 2026;389:114404. doi:10.1016/j.jconrel.2025.114404
BibTeX
@article{Luo2026,
author = {Luo, Haixia and Wang, Kexin and Zhang, Yan and Li, Tiantian and Jia, Xiaojie and Feng, Renqian and Zhao, Ran and Yu, Rui and Hu, Lang and Zhang, Mingming and Qi, Bingchao and Li, Yan},
title = {Targeted engineered exosomes alleviate myocardial infarction injury by enhancing angiogenesis and improving mitochondrial function},
journal = {Journal of Controlled Release},
year = {2026},
volume = {389},
pages = {114404},
doi = {10.1016/j.jconrel.2025.114404}
}
EUVIMED